D-erythro-Sphingosine
Based on 4 publication(s) in Google Scholar
D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 123-78-4
- Formula: C18H37NO2
- Molecular Weight:299.49
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) D-erythro-Sphingosine
More-
WB
-
RT-PCR
-
Bio/Physico-chemical Assay
-
WB
-
IF
All Endogenous Metabolite Isoforms
More
Biological Activity
|
p32 8 μM (EC50) |
PKC |
PP2A |
Human Endogenous Metabolite |
Microbial Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| FL5.12 | IC50 |
3.6 μM
Compound: 6
|
Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis
Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis
|
[PMID: 27475534] |
| Jurkat | IC50 |
2.01 μM
Compound: Sphingosine
|
Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay
Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay
|
[PMID: 17400555] |
| Jurkat | IC50 |
2.88 μM
Compound: Sphingosine
|
Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay
Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay
|
[PMID: 17400555] |
| Jurkat | IC50 |
3.38 μM
Compound: Sphingosine
|
Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay
Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay
|
[PMID: 17400555] |
| Jurkat | IC50 |
3.48 μM
Compound: Sphingosine
|
Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay
Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay
|
[PMID: 17400555] |
A p32-sphingosine-activated protein kinase responds to low concentrations of D-erythro-Sphingosine with an initial activation observed at 2.5 μM and a peak activity at 10-20 μM. This kinase shows a modest specificity for D-erythro-Sphingosine over other sphingosine tereoisomers, and a preference for sphingosines over ihydrosphingosines[1]. D-erythro-Sphingosine inhibits protein kinase C in vitro[2]. D-erythro-Sphingosine has been shown to inhibit protein kinase C, which affects cell regulation and several signal transduction pathways, and exhibits antitumor promoter activities in various mammalian cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 123-78-4
-
Appearance Solid
-
Molecular Weight 299.49
-
Formula C18H37NO2
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO
-
Synonyms
Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2024 Sep 19;15(1):8221. PMID: 39300135
D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 19;15(1):8221. [Abstract]
D-erythro-Sphingosine (10 μM, 30 min). Effects of sph addition in different ways in ZIKV-infected cells. The protein levels were quantified using western blot at 48 h post infection. Con.: DMSO treatment.
D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 19;15(1):8221. [Abstract]
D-erythro-Sphingosine (10 μM, 30 min). Effects of sph addition in different ways in ZIKV-infected cells. ZIKV mRNA levels were examined using qPCR (b; n = 3 biologically independent cell samples; two-sided multiple unpaired t-test) at 48 h post infection. Con.: DMSO treatment.
-
Mol Med
Acid ceramidase targeting pyruvate kinase affected trypsinogen activation in acute pancreatitis. [Abstract]2022 Sep 6;28(1):106. PMID: 36068514
D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Mol Med. 2022 Sep 6;28(1):106. [Abstract]
Primary cells were treated with solvent, 5 μM of sphingosine, 10 μM of DASA58 plus sphingosine, and 200 nM of cerulein plus 10 ng/mL of LPS and DASA58 with LPS and sphingosine for 6 h. Cells were lysed for trypsin assay.
D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Mol Med. 2022 Sep 6;28(1):106. [Abstract]
Primary cells were treated with solvent, 5 μM of sphingosine, 10 μM of DASA58 plus sphingosine, and 200 nM of cerulein plus 10 ng/mL of LPS and DASA58 with LPS and sphingosine for 6 h. Cells were lysed for cathepsin B assay by WB.
D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Mol Med. 2022 Sep 6;28(1):106. [Abstract]
Acid ceramidase (ASAH1) regulated the activity of trypsin and cathepsin B through sphingosine (SPH). Lentivirus particles containing nontargeting shRNA/Control vector or shRNA targeting ASAH1/ASAH1 expressing plasmid were added to primary pancreatic acinar cells. Additionally, the cells were treated as indicated. Cathepsin B activity was detected by a spectrophotometer.
-
J Agric Food Chem
Chronic Exposure to Environmentally Relevant Concentrations of Microcystin-Leucine Arginine Causes Lung Barrier Damage through PP2A Activity Inhibition and Claudin1 Ubiquitination. [Abstract]2022 Sep 7;70(35):10907-10918. PMID: 36026589 -
Mol Neurobiol
Microcystin-LR Exposure Damages Neurons by Inducing α-Syn Aggregation via MAPK4/GATA2/SNCA and PP2A/GRKs Pathways. [Abstract]2025 May;62(5):6195-6211. PMID: 39738876
Solvent & Solubility
DMSO : 50 mg/mL (166.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703. [Content Brief]
[2]. Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91. [Content Brief]
[3]. Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7. [Content Brief]
[4]. Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3390 mL | 16.6950 mL | 33.3901 mL | 83.4752 mL |
| 5 mM | 0.6678 mL | 3.3390 mL | 6.6780 mL | 16.6950 mL | |
| 10 mM | 0.3339 mL | 1.6695 mL | 3.3390 mL | 8.3475 mL | |
| 15 mM | 0.2226 mL | 1.1130 mL | 2.2260 mL | 5.5650 mL | |
| 20 mM | 0.1670 mL | 0.8348 mL | 1.6695 mL | 4.1738 mL | |
| 25 mM | 0.1336 mL | 0.6678 mL | 1.3356 mL | 3.3390 mL | |
| 30 mM | 0.1113 mL | 0.5565 mL | 1.1130 mL | 2.7825 mL | |
| 40 mM | 0.0835 mL | 0.4174 mL | 0.8348 mL | 2.0869 mL | |
| 50 mM | 0.0668 mL | 0.3339 mL | 0.6678 mL | 1.6695 mL | |
| 60 mM | 0.0557 mL | 0.2783 mL | 0.5565 mL | 1.3913 mL | |
| 80 mM | 0.0417 mL | 0.2087 mL | 0.4174 mL | 1.0434 mL | |
| 100 mM | 0.0334 mL | 0.1670 mL | 0.3339 mL | 0.8348 mL |